Community cardiovascular disease risk from cross-sectional general practice clinical data: a spatial analysis by Bagheri, Nasser et al.
PREVENTING  CHRONIC  DISEASE
P U B L I C  H E A L T H  R E S E A R C H ,  P R A C T I C E ,  A N D  P O L I C Y 
  Volume 12, E26                                                                         FEBRUARY 2015  
 
ORIGINAL RESEARCH
 
 
Community Cardiovascular Disease Risk
From Cross-Sectional General Practice
Clinical Data: A Spatial Analysis
 
Nasser Bagheri, PhD; Bridget Gilmour; Ian McRae, PhD; Paul Konings;
Paresh Dawda, MBBS; Peter Del Fante, MBBS; Chris van Weel, MD, PhD 
 
Suggested  citation  for  this  article:  Bagheri N,  Gilmour B,
McRae I, Konings P, Dawda P, Del Fante P, et al.  Community
Cardiovascular  Disease  Risk  From  Cross-Sectional  General
Practice  Clinical  Data:  A  Spatial  Analysis.  Prev  Chronic  Dis
2015;12:140379. DOI: http://dx.doi.org/10.5888/pcd12.140379.
PEER REVIEWED
Abstract
Introduction
Cardiovascular disease (CVD) continues to be a leading cause of
illness and death among adults worldwide. The objective of this
study was to calculate a CVD risk score from general practice
(GP) clinical records and assess spatial variations of CVD risk in
communities.
Methods
We used GP clinical data for 4,740 men and women aged 30 to 74
years with no history of CVD. A 10-year absolute CVD risk score
was calculated based on the Framingham risk equation. The indi-
vidual risk scores were aggregated within each Statistical Area
Level One (SA1) to predict the level of CVD risk in that area. Fi-
nally, the pattern of CVD risk was visualized to highlight com-
munities with high and low risk of CVD.
Results
The overall 10-year risk of CVD in our sample population was
14.6% (95% confidence  interval  [CI],  14.3%–14.9%).  Of  the
4,740 patients in our study, 26.7% were at high risk, 29.8% were
at moderate risk, and 43.5% were at low risk for CVD over 10
years. The proportion of patients at high risk for CVD was signi-
ficantly higher in the communities of low socioeconomic status.
Conclusion
This study illustrates methods to further explore prevalence, loca-
tion, and correlates of CVD to identify communities of high levels
of unmet need for cardiovascular care and to enable geographic
targeting of effective interventions for enhancing early and timely
detection and management of CVD in those communities.
Introduction
Cardiovascular disease (CVD) is a leading cause of death and dis-
ease burden across the world, and the burden is expected to in-
crease as the population ages (1–3). CVD is the most expensive
disease  in  Australia;  it  accounted for  $7.9  billion,  or  11%, of
health spending from 2009 to 2010 (1).
The most  commonly used CVD risk prediction algorithms are
those derived from the Framingham Risk Equation (FRE), which
is used in general practice (GP) to assess risks for individual pa-
tients (4). The trend in primary prevention of CVD in GPs has
been to move away from assessment of relative CVD risk factors
toward assessment and management of these factors as absolute
CVD risk (5,6).
Best-value prevention strategies require knowledge and contextu-
alized understanding of people, communities, and environments,
as well as variations in CVD risk. Although clinically proven tools
are available for assessing risk factors in individuals, most at-risk
individuals never take part in such assessment until disease pro-
gression is under way. Although imprecise proxies for risk can be
used to make community-based risk estimates, there is still a con-
siderable knowledge gap; no fine-grained population tools exist to
directly predict “hotspots” for future CVD risk from GP clinical
data.
Few studies have attempted to examine spatial variation of CVD
risk at a smaller geographic scale across the world. Noble et al ex-
amined the feasibility of mapping chronic disease risk in general
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and created a small-area map of diabetes risk from GP clinical re-
cords in the United Kingdom (7). In Australia, Tideman et al com-
pared the CVD risk of a population survey sample from northwest
Adelaide with a nearby rural population but did not look at the
variation within the survey population catchment (8). This is the
first study that visualizes the pattern of CVD risk at a small-area
scale from GP clinical records to explore possible clusters or hot-
spots of CVD risk in communities. The small area used, Statistic-
al Area Level 1 (SA1), has a population size between 200 to 800
people, which is approximately equal to the size of a US census
block (315 people on average) (9).
The main objective of this study was to explore patterns of CVD
risk in people across small areas and investigate the association
between area-level socioeconomic status and CVD risk patterns.
This approach allows the production of fine-grained maps of CVD
risk for use by clinicians and policy makers to enable geographic
targeting of interventions in communities.
Methods
Data sources
De-identified clinical practice data from 2010 through 2012 were
drawn from a large, multisite GP in northwest Adelaide in South
Australia at the end of 2012. The data were linked to SA1s using
methods described by Mazumdar et al in 2014 (10). There are 148
SA1s in the study area, and 14 other general practices operate in
the same area.  Although patients came from a wide area,  they
were concentrated on the LeFevre Peninsula and comprised 18%
of the population of this area. Overall, data on 14,969 active pa-
tients were extracted from the practice; 8,630 of these patients
were aged 30 to 74 years with no prior history of CVD (ie, stroke,
chronic heart disease, peripheral vascular disease, or heart failure).
Patients were excluded if data were not available for 7 risk factors
for CVD, which are required to calculate the FRE. A major part of
the analysis was based on geography, so the patients were classi-
fied according to the SA1 in which they resided. The patients from
the clinic mostly resided on the LeFevre Peninsula and in sur-
rounding areas, but some came from farther distances. To main-
tain confidentiality, the study excluded those SA1s that contained
fewer than 5 patients (701 patients in total), leaving a sample of
4,740  patients.  Under  Australian  health  care,  patients  access
primary health care as the point of entry into the health care sys-
tem, and each year approximately 85% of the population has con-
tact with a GP. Therefore, to the degree that GPs choose to parti-
cipate in studies such as this one, it is possible to obtain high pa-
tient coverage.
Characteristics associated with CVD risk and
identifying areas of high risk
We used the FRE to evaluate 5-year and 10-year absolute risks of
CVD for individuals based on GP clinical data for the northwest
Adelaide area. The FRE, a risk model designed for use on indi-
viduals’ clinical data, is well-suited for producing population-level
risk estimates (11,12). The FRE accounts for age, sex, total cho-
lesterol, high-density lipoprotein cholesterol, systolic blood pres-
sure, smoking status, and whether a patient has diabetes to estim-
ate the patient’s risk for developing CVD in the next 10 years. The
recommended scoring system has been in use since 1991 (13). We
also calculated patients’ 5-year risk of CVD using the FRE and
compared these data with the 10-year data to assess patterns.
The National Vascular Disease Prevention Alliance in Australia
defined CVD risk category on the basis of FRE as follows: an ab-
solute risk of CVD events over 10 years higher than 20% is high
risk, from 10% to 20% is moderate risk, and less than 10% is low
risk. Body mass index (BMI, kg/m2) was not used in the FRE, but
because it is a major risk factor for CVD we included the distribu-
tion of CVD risk by BMI category. We used World Health Organ-
ization  recommendations  for  BMI cut-offs  as  follows:  under-
weight, less than 18.5; normal weight, 18.5 to 24.9; overweight
25.0 to 29.9; and obese, 30.0 or higher.
First, we linked the de-identified patient records, including calcu-
lated absolute 5-year and 10-year CVD risk, to the corresponding
SA1 within the practice catchment. Second, the individual risk
scores were aggregated to SA1 level by calculating mean risk for
each SA1. Third, the area level of CVD risk was visualized to ex-
amine the areas of high and low probability of developing CVD
risk over the next 10 years in the study area.
An index  of  relative  socioeconomic  disadvantage  (IRSD)  de-
veloped by the Australian Bureau of Statistics was linked to the
corresponding SA1 to make comparisons with the pattern of abso-
lute CVD risk (14,15). IRSD is a general socioeconomic index de-
rived from census variables related to disadvantage, such as low
income, low educational attainment, unemployment, and dwell-
ings without motor vehicles. We ran a linear regression model to
investigate the relationship between CVD risk and ISRD, adjust-
ing for demographic variables.
To identify areas with high risk (hotspots) and low risk (coldspots)
for CVD, a continuous heat map of CVD risk was generated using
the inverse distance weighting (IDW) technique. The IDW tech-
nique generates an interpolated and smoothed risk surface, with an
anticipated statistical resolution at neighborhood (or community)
level to accurately identify high-risk areas (16). Cluster and out-
lier analysis with Anselin local Moran’s I and Getis-Ord G tech-
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niques were used to investigate potential clusters of hotspots in the
study areas (Appendix). We compared IDW with Natural Neigh-
bor and kriging smoothing methods (17). However, the output pat-
tern for these 2 techniques was the same. The parameters included
to generate a smoothed pattern in the IDW method include Man-
hattan distance as distance parameter, number of units (12 points),
and centroids of each SA1. The tertile of the index of relative so-
cioeconomic disadvantage was mapped for each SA1 to compare
with the pattern of CVD risk at the SA1 level in the study area
(11).
We used Stata version 12.1 (StataCorp, LP) to calculate the CVD
risk scores and conduct descriptive analyses for our sample popu-
lation and ArcGIS version 10.2 (Esri) to conduct spatial analyses
and mapping. The spatial analysis was restricted to the LeFevre
Peninsula area of the GP catchment, where there was the highest
penetration of the practice; therefore, the mapped data are in an
area where the numbers of patients are larger and estimated risks
more stable. The study obtained ethics approval from the Australi-
an National University human ethics committee (protocol 2014/
174).
Results
Patient characteristics
Overall, patients who were male, smokers, overweight or obese,
living in  low socioeconomic areas  (Table),  and who had high
blood pressure and total cholesterol had higher prevalence of CVD
risk over 5 or 10 years than did their counterparts. The overall 5-
and 10-year CVD risk in people aged 30 to 74 years at the GP
level  was  6.8%  (95%  CI,  6.6%–7.0%)  and  14.6%  (95%  CI,
14.3%–14.9%), respectively. The percentage of sample popula-
tion with high risk was 26.6%, moderate risk was 30.0%, and low
risk was 43.6%. Both 5-year and 10-year CVD risk rose as BMI
values increased.
Spatial pattern of CVD risk and socioeconomic
status
The most disadvantaged population lives in the eastern part of the
study area near the industrialized regions, and the least disadvant-
aged population lives in the western beach areas (Figure 1). The
overall pattern of 10-year risk of CVD varied across the SA1s
(range, 6%–28%). The 10-year CVD risk was significantly higher
in the most disadvantaged areas (16.4%) than the least disadvant-
aged areas (13.4%) (Table).
Figure 1. Pattern of an index of relative socioeconomic disadvantage in study
area, Adelaide, Australia, 2012.
 
The interpolated surface of the 10-year CVD risk shows clusters
(risk of CVD) across the study area (Figure 2). The hotspots are
seen in the most disadvantaged areas in the eastern and central
parts of the LeFevre Peninsula. Clusters with high CVD risk val-
ues were significantly different from neighboring clusters’ CVD
risk values (z score, 2.16; P = .03).
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Figure 2. Smoothed pattern of cardiovascular disease risk in the study area,
Adelaide, Australia, 2012.
 
The number of active patients varied from 5 to 151 (median,16)
across the SA1s in the study area. However, very few SA1s were
small; only 4% of SA1s with high CVD risk had greater than 5
and fewer than 10 patients. This rate was 6% for low CVD risk
areas.
Statistical and visual comparison of the spatial pattern of CVD
risk  with  the  IRSD  pattern  indicates  that  the  risk  of  CVD  is
highest in the most disadvantaged areas, consistent with the res-
ults shown in Table 1 and Figure 2. Furthermore, the regression
model results showed a significant negative relationship between
CVD risk and IRSD (P < .001), which means CVD risk is more
prevalent in disadvantaged areas.
Discussion
This research aimed to identify area-level CVD risk and the pro-
portion of the population at high risk using GP clinical records.
Patients’ 5- and 10-year risk scores were generated on the basis of
the Framingham risk prediction model, and these estimated scores
were aggregated and visualized at the SA1 level. Finally a “heat
map” interpolation surface of CVD risk was created to highlight
the hotspots (high-risk areas) and coldspots (low-risk areas) in the
study area. To our knowledge this is the first time area-level CVD
risk, hotspots, and clustering in CVD risk have been studied using
de-identified GP clinical records. We found that the proportion of
patients at high risk for CVD risk was significantly higher in the
communities of low socioeconomic status than in those of high so-
cioeconomic status.
A considerable amount of literature has been published on the
validity and generalizability of the FRE, which has been recom-
mended as the most reliable method of predicting CVD risk in the
United States (18–20). Many studies have demonstrated that the
Framingham method of predicting risk is accurate when used on
other populations, including most Australians and Dutch people
(21–23). However, it is not generalizable to every population, and
it  can significantly underestimate the CVD risk of  Aborigines
(24). The Aboriginal data were poorly recorded in our GP dataset,
so we were not able to evaluate a CVD risk pattern in Aboriginal
people. However, the proportion of Aboriginal and Torres Strait
Islander people in the general population in our study area was ap-
proximately 2%. Regardless of its limitations, the FRE is recom-
mended by the National Heart Foundation of Australia to calcu-
late CVD risk of Australians (25).
Of 4,740 patients aged 30 or older, 1,260 (26.6%) had a 10-year
CVD risk score of greater than 20%. This proportion is higher
than expected (16%–20%) (26). However, this finding may have
been related to the fact that most patients in the sample were over-
weight or obese (81%), older (68% older than 50 years), and dia-
betic (10.1%). As the number of patients in each SA1 varied, and
in some cases was quite small, CVD risk varied not only due to
“real” effects but also to sample size variability. We expected to
overestimate the overall CVD risk, in particular, for the younger
age groups. For example, of 716 active patients in the age range
30 to 34 years, we had data for all the risk factors on only 179 pa-
tients. Doctors may not have considered the other 537 patients to
be at high risk of CVD and thus did not feel it was necessary to
measure, for example, their cholesterol levels. However, the 179
patients for whom who we did have a complete data set were more
likely to have obvious risk factors, such as obesity, which would
have compelled their doctors to make all the measurements with
which to calculate CVD risk. Therefore, the patients whose data
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we were missing may be at lower risk for CVD; consequently, we
may have overestimated CVD risk for this population, and ana-
lyses on a larger sample are recommended.
Furthermore, we looked at SA1 level CVD risk patterns for pa-
tients who were older than 70 years. The CVD risk maps were
flattened for 78% of SA1s with a CVD risk of greater than 20%
(high risk) in the study area. We compared the age and sex pattern
of the analysis sample (4,740) with the entire original cohort of
14,969 and population aged 30 to 74 years (38,770) for the geo-
graphic area of interest (Appendix). The analysis sample com-
prises an older population, but the original cohort is much the
same as the overall population. For example, the percentages of
population older than 40 years are 90% in the analysis sample,
86% in the original cohort, and 78% in the area of geographic in-
terest. The greater CVD risk in older patients is unsurprising, be-
cause this group usually has higher prevalence of CVD risk factors
compared with other adults. Similar findings were seen among
American adults aged 20 years or older and Canadian adults aged
30 to 74 years who participated in a cross-sectional sample of
5,440 and 1,293, respectively (27,28).
This research addressed a significant public health problem, that of
identifying the spatial distribution of CVD risk in Australia in a
timely way so that prevention services can be more efficiently dis-
tributed. This project also allows risk profiles to be considered in
relation to socioeconomic characteristics of areas. Consequently,
our approach may be useful in describing and exploring spatial in-
equalities in the distribution of CVD risk, or any chronic disease
for which risk modeling is available, that contributes to our under-
standing of health inequalities.
The development of a tool for monitoring disease risk has the po-
tential to improve service delivery, policy development, research,
and ultimately health outcomes, which would be particularly bene-
ficial for people living in underserviced areas. No tools exist in
Australia to predict risk hotspots in a timely manner, which means
that development of chronic disease prevention policies at the na-
tional, state, and local levels are not informed by the most current
information about disease risk in specific populations. Addition-
ally,  this  method  enables  ecological  studies  of  relationship
between the area risk and socioeconomic status and built environ-
ment characteristics such as access to green spaces and fast-food
outlets. This method can be used to estimate prevalence of CVD
risk at different geographical scales from GP catchments to the na-
tional level, using demographic and clinical risk factors.
A limitation of this study is that the FRE may underestimate risk
for people who take lipid-lowering or antihypertensive medica-
tion or people who have recently stopped smoking (29). However,
current clinical practice is to calculate people’s risk even if they
are taking medications (30).
The spatial analysis indicated that high CVD risk clusters were
located in the most disadvantaged areas. This finding suggests that
public health policy makers should focus on these hotspots and
plan for active case finding (eg, screening tests) to operate early
preventive interventions to reduce population CVD risk in those
areas.
This approach provides an opportunity for researchers who have
access to GP-based clinical data to further explore prevalence, loc-
ation, and correlates of CVD and is applicable anywhere that these
data are available. This method can be used as a tool to identify
areas of high levels of unmet need for cardiovascular care, which
could enable geographic targeting of effective interventions for en-
hancing early and timely detection and management of CVD in
those communities. Furthermore, this study demonstrates that GP
data can help identify public health priorities.
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Table
Table. Cohort (N = 4,740) Characteristics and 5-Year and 10-Year Cardiovascular Disease (CVD) Risk at General Practice
Level, Adelaide, Australia, 2012
Characteristic No. (%) 5-Year CVD Risk, % 10-Year CVD Risk, %
Agea, y
30–34 179 (3.8) 0.6 1.8
35–39 287 (6.0) 1.3 3.6
40–44 441 (9.3) 2.6 6.5
45–49 579 (12.2) 3.8 9.1
50–54 807 (17.0) 5.4 12.3
55–59 779 (16.4) 7.3 15.8
60–64 761 (16.0) 9.6 19.9
65–69 502 (10.6) 11.0 22.3
70–74 405 (8.5) 14.1 27.2
Sexa
Male 1,990 (42.0) 9.9 20.2
Female 2,750 (58.0) 4.6 10.5
Body mass index categoryb (kg/m2)
Underweight (<18.5) 14 (0.6) 2.3 5.5
Normal (18.5–24.9) 399 (18.4) 5.2 11.4
Overweight (25.0–29.9) 723 (33.3) 7.0 14.9
Obese (≥30.0) 1,036 (47.7) 8.6 17.6
Smoking statusa
Smoker 2,206 (46.5) 9.5 19.5
Nonsmoker 2,534 (53.5) 4.5 10.3
Index of relative socioeconomic disadvantage
Most disadvantaged areas 1,461 (30.8) 7.9 16.4
Moderately disadvantaged areas 1,604 (33.8) 6.6 14.2
Least disadvantaged areas 1,675 (35.3) 6.2 13.4
Total 4,740 (100.0) 6.8c 14.6d
a Risk factor was included in the Framingham equation.
b Data were available for body mass index for only 45.8% of the sample, so the total number of patients in this category does not sum to 4,740.
c 95% Confidence interval, 6.6%–7.0%.
d 95% Confidence interval, 14.3%–14.9%.
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Appendix.
Clusters of hotspots in the study areas, Adelaide, Australia, 2012. [This file is available for download as a Microsoft Word doc-
ument.]
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